A Pharmacokinetic–Viral Kinetic Model Describes the Effect of Alisporivir as Monotherapy or in Combination With Peg‐IFN on Hepatitis C Virologic Response

Publisher： John Wiley & Sons Inc

E-ISSN： 1532-6535|96|5|599-608

ISSN： 0009-9236

Source： CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol.96, Iss.5, 2014-11, pp. : 599-608

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Comparison of the Exponential Decay Slope between PEG-IFN alfa-2b/Ribavirin and IFN alfa-2b/Ribavirin Combination Therapy in Patients with Chronic Hepatitis C Genotype 1b Infection and a High Viral Load

By  

Intervirology, Vol. 47, Iss. 2, 2004-06 ,pp. : 102-107

Karger

Access to resources Recommend Favorite

Usefulness of a New Immunoradiometric Assay of HCV Core Antigen to Predict Virological Response during PEG-IFN/RBV Combination Therapy for Chronic Hepatitis with High Viral Load of Serum HCV RNA Genotype 1b

By  

Intervirology, Vol. 51, Iss. 1, 2008-06 ,pp. : 70-75

Karger

Access to resources Recommend Favorite

PEG-IFNα/RBV Combination Therapy for Chronic Hepatitis C Patients Increases Serum Ferritin Level while It Improves Sustained Viral Response Rate

By  

Intervirology, Vol. 53, Iss. 1, 2010-01 ,pp. : 60-65

Karger

Access to resources Recommend Favorite

Prolonged PEG-IFN and RBV Is Effective in Patients with HCV Genotype 1 and High Viral Load Who Achieved Virological Response Later than 24 Weeks

By  

Intervirology, Vol. 53, Iss. 1, 2010-01 ,pp. : 55-59

Karger

Access to resources Recommend Favorite

High Sustained Virologic Response Rate after Interferon Monotherapy in Japanese Hepatitis C Patients with a Low HCV RNA Titer and/or HCV Genotype 2

By  

Intervirology, Vol. 47, Iss. 6, 2004-11 ,pp. : 328-334

Karger

Access to resources Recommend Favorite